The House Oversight Committee held its third hearing on pharmacy benefit manager reforms in 14 months, but could not elicit an admission from executives that they are responsible for increasing drug prices.

Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

Deal Snapshot: Novartis partnered with IFM Due in 2019 and has now exercised an option to buy the IFM Therapeutics subsidiary, continuing its ongoing relationship with the group.